Effective Primary Prevention of Atopic Dermatitis in High-Risk Neonates via Moisturizer Application: Protocol for a

Yusuke Inuzuka1, Kiwako Yamamoto-Hanada1, Kyongsun Pak2

  • 1Allergy Center, National Center for Child Health and Development, Tokyo, Japan.

Frontiers in Allergy
|June 30, 2022
PubMed

Insights

Twice daily application of Fam's Baby™ moisturizer may be more effective than once daily application for preventing atopic dermatitis (AD) in infants. This study compares Fam's Baby™ and 2e moisturizers to find optimal prevention strategies.

Area of Science:

  • Dermatology
  • Neonatal Care
  • Clinical Trials

Background:

  • Atopic dermatitis (AD) is a chronic inflammatory skin condition impacting infant quality of life.
  • Previous findings on moisturizer 2e for AD prevention are inconsistent, necessitating further research.
  • Optimal moisturizer type and application frequency for infant AD prevention remain undetermined.

Purpose of the Study:

  • To compare the efficacy of twice daily versus once daily application of Fam's Baby™ moisturizer.
  • To evaluate once daily application of 2e moisturizer as a control.
  • To determine the optimal moisturizer regimen for preventing AD in neonates and infants.

Main Methods:

  • A single-center, phase II, randomized controlled trial involving 60 newborns.
  • Participants are assigned to one of three groups: Fam's Baby™ twice daily, Fam's Baby™ once daily, or 2e once daily.
  • The primary outcome is the time to the first onset of AD.

Main Results:

  • This section is not available in the provided abstract.
  • Further research is needed to determine the efficacy of different moisturizer application frequencies.
  • The study aims to inform future phase III trials for definitive conclusions.

Conclusions:

  • This trial is the first in Japan to assess Fam's Baby™ for AD prevention in infants.
  • Results will guide a potential phase III study on optimal AD prevention through moisturizers.
  • The study anticipates contributing to reduced AD prevalence and healthcare costs.
Abstract

Related Concept Videos

Clinical Applications of Epidermal Stem Cells01:19

Clinical Applications of Epidermal Stem Cells

Epidermal stem cells (EpiSCs) are mainly located at the basal layer of the epidermis. These cells repair minor injuries of the skin and replace dead skin cells. However, EpiSCs’ cannot heal severe wounds such as major burns or those from diabetes or hereditary disorders. In such cases, culturing the epidermal stem cells from the patient is possible and has yielded successful treatment options, such as laboratory-grown skin grafts. These grafts are synthesized using a patient’s own...
2.7K
Renewal of Skin Epidermal Stem Cells01:12

Renewal of Skin Epidermal Stem Cells

The skin is divided into epidermis, dermis, and hypodermis, the skin's outermost, middle, and inner layers. The human epidermal layer regularly undergoes renewal, where old, dead cells are replaced by new cells. Epidermal stem cells or EpiSCs divide and differentiate to restore the lost cells. For the renewal process, some EpiSCs continuously self-renew. In contrast, few others differentiate into transit-amplifying cells, which later form prickle or spinous cells, followed by granular...
2.6K
Healthcare Associated Infections II: Preventive Measures01:22

Healthcare Associated Infections II: Preventive Measures

Essential infection prevention measures are based on the knowledge of the infection chain, the modes of transmission in healthcare settings, and the use of the best practices in all healthcare settings. Compulsory public reporting of healthcare-associated infection rates is needed to allow individuals and the community to make informed choices regarding selecting a healthcare facility.
The best practices for preventing healthcare-associated infections include hand hygiene, patient risk...
2.8K